Over the last 20 years, it has emerged that, while surgical revascularisation of extensive ischaemic heart disease may have prognostic advantages, the main issues considered regarding individual management are usually those of symptomatic improvement only. The major impetus towards invasive intervention is therefore failure of prophylactic anti-anginal therapy. On the other hand, many patients, especially the elderly, now present the clinical problem of ongoing angina without residual invasive options. There is an ongoing need for more effective anti-anginal therapies. Of the currently available major classes of prophylactic anti-anginal agents, neither nitrates, β-blockers nor calcium antagonists generally produce marked improvements in exercise duration. Three areas of new therapeutic development in anti-anginal therapy are worthy of note. These involve the sinus node inhibitor ivabradine, high dose allopurinol (xanthine oxidase inhibitor) and a new class of "metabolic modulators" represented by perhexiline, trimetazidine and probably ranolazine. The current review addresses the therapeutic potential of these agents. Notably, all of these "new" drugs are potentially suitable for management of angina in the setting of impaired left ventricular systolic function, and they may also be utilized in patients with angina independent of the presence of coronary disease (for example in hypertrophic cardiomyopathy). The current evidence for efficacy and potential future development in this area are reviewed.
Introduction
"If I were an ischaemic cardiac cell, and someone offered me drugs or blood, I think I'd take blood!" -Dr. W. Paulus, 1986 The history of development of anti-ischaemic therapy for angina pectoris has been bedevilled by the notion that a strategy of predominantly medical treatment is essentially palliative, while interventional restoration of normal coronary haemodynamics is "curative". Interestingly, evidence to support this philosophy in patients with stable angina is very limited, beyond the findings of the CASS study more than 25 years ago [1] . Notably, the results of the COURAGE trial [2] challenge the idea that coronary stenting should play a primary role in such patients.
If therefore the major efficacy of drugs of surgical/percutaneous intervention relates to amelioration of symptoms in patients with angina, how effective are our "core" medical anti-anginal therapies? The major groups of prophylactic anti-anginal agents are long-acting nitrates, β-blockers and calcium antagonists (especially nondihydropyridine agents such as verapamil and diltiazem). The key findings from studies of mono-therapy with these agents are summarized in Table 1 , and the "core" mechanisms of action of these agents are schematized in Figure 1 .
In general, these show that long-acting nitrates and β-blockers induce only small prolongations of exercise duration, while both verapamil and diltiazem are a little more effective. On the other hand, there is no evidence that any of these forms of therapy improves long-term outcomes in patients with stable angina (although admittedly β-blockers have prognostic utility if patients have concomitant heart failure). Indeed, there is a concern that long-acting nitrates may have a number of important disadvantages, including potential aggravation of endothelial dysfunction [3] and also the precipitation of "rebound" ischaemia [4] . Interestingly, nicoradil, an organic nitrate/potassium channel activation, appears to reduce risk of hospitalization during chronic therapy [5] although the mechanism(s) of this beneficial effect remain uncertain.
The clinical characteristics of patients treated medically for angina pectoris have also evolved with the relatively widespread availability of coronary surgery/stenting. In most societies, such patients now tend to be elderly, with multiple comorbidities. Many such patients have undergone surgical interventions previously and are technically unsuitable for further invasive procedures: many have concomitant severe impairment of left ventri- cular systolic function. In such individuals, there is a clear-cut need for a transition to "new" anti-anginal therapies. Notably, treatment with verapamil or diltiazem is contra-indicated in the presence of severe systolic heart failure [6] . This review addresses the evolving role of a number of newly recognised/developed anti-anginal agents in the setting of "difficult" angina pectoris. The major sites of action of these agents in ameliorating ischaemia are schematized in Figure 1 . A potential role for all of these agents in angina pectoris refractory or unsuitable for β-blockers or calcium antagonists was also included in current textbook recommendations [7] .
Ivabradine
Ivabradine is a sino-atrial node inhibitor which specifically inhibits the If channel of pacemaker cells, leading to a reduction in both resting and exercise-induced heart rate and improvement in myocardial O 2 balance. It has no effect on other intracardiac conduction system as well as on blood pressure and myocardial contractility. Because of these limited sites of action, it will not induce bronchospasm (unlike β-blockers), it is devoid of interactions with diabetic status, and does not adversely affect symptomatic status in the presence of systolic heart failure. On the other hand, it is totally ineffective in patients with no sinus node activity (e.g. atrial fibrillation).
To date, ivabradine has been evaluated as an anti-anginal agent both in monotherapy and in combination with β-blockers, as summarized in Table 2 . In both circumstances, there was a moderate increase in exercise duration. The only common adverse effects seen were those of phosphenes (flashing lights) development, due to If current inhibition in the retina. Interestingly, recent clinical trial developments with ivabradine have focused mainly on its role as a secondary treatment in heart failure [8] . No long-term data are available regarding effects on cardiovascular events.
High Dose Allopurinol
One other agent that has been proposed as an anti-anginal recently is allopurinol, a xanthine oxidase inhibitor. Allopurinol has been traditionally used in the treatment of gout. The application of allopurinol in coronary artery disease is based on previous evidence that xanthine oxidase is a potent mediator of oxidative stress. Indeed early studies have shown the potential of allopurinol to reduce vascular oxidative stress and thereby improve endothelial function [9] . Furthermore, alterations in cardiac metabolism, primarily in oxygen consumption and contractility have been demonstrated in heart failure models with allopurinol [10] [11]. The first randomized double-blind placebo controlled trial of the use of allopurinol in the management of stable angina, offered promising results. In this study, 65 patients with documented coronary artery disease and positive exercise test were randomized to receive high dose allopurinol, 600 mg a day on top of a standard treatment, in a double-blinded controlled trial [12] . Allopurinol use was associated with a median increase in exercise time to ST-segment depression of 43 seconds (p = 0.0002), a median increase in total exercise time of 58 seconds (p = 0.0003), and a median increase in time to chest pain of 38 seconds (p = 0.001). These findings were backed up by a second study by the same group, which explored the potential mechanisms of the benefits of allopurinol in 80 patients with stable coronary artery disease, on maximal anti-anginal treatment [13] . Endothelial function was assessed by forearm venous occlusion plethysmography, flow-mediated dilation, and pulse wave analysis and vascular oxidative stress was assessed by intra-arterial co-infusion of vitamin C and acetylcholine. They found that indeed allopurinol use was associated with improved endothelium-dependent vasodilation, by both forearm venous occlusion plethysmography (93% ± 67% vs. 145% ± 106%, p = 0.006) and flow-mediated dilation (4.2% ± 1.8% vs. 5.4% ± 1.7%, p < 0.001). Arterial stiffness was also improved significantly (central augmentation index improved by 2.6% ± 7.0%, p < 0.001), and furthermore, vascular oxidative stress was completely abolished by allopurinol.
However, these studies are small and although no adverse effects were reported, further data in regards to safety and impact on long term cardiovascular outcomes in larger studies are prudent. More importantly, it is as yet unclear whether addition of allopurinol to other anti-anginal drugs improves long-term prognosis in patient with CAD. We have also seen benefits in similar small animal and human studies with allopurinol in congestive heart failure [9] , and yet the recent large clinical trial OPT-CHF in 405 patients failed to produce any clinical benefits [14] .
Agents Modifying Myocardial Metabolism
The association of exertional ischaemia with impairment of myocardial energetics raises the option of addressing this problem without either limiting myocardial work (for example by preventing tachycardia and/or exercise-induced increases in contractile function) or by improving coronary haemodynamics.
In theory, the generation of high energy phosphates by the myocardium should be critical to maintenance of homeostasis irrespective of whether the underlying problem is limitation of myocardial perfusion, increased left ventricular afterload (for example with aortic valvular stenosis) or even impairment of systolic and/or diastolic left ventricular dysfunction. However, pharmacological manipulation of myocardial energetics has been a slowly evolving area.
Initial attempts to "feed the heart" were associated with treatment for evolving myocardial infarction, where the glucose-insulin-potassium (GIK) treatment algorithm was proposed and then tried extensively (for review see [15] ). Interestingly, this idea of promoting glucose uptake and utilization has generally been unsuccessful, with the possible exception of prevention of myocardial ischaemia associated with open-heart surgery [16] .
Subsequently, there have been extensive developments of drugs which potentially affect myocardial energetics during chronic oral administration. Some of these agents inhibit long-chain fatty acid catabolism, whether via inhibiting the "carnitine shuttle" (which controls their uptake into mitochondria) or fatty acid oxidases. Such agents may activate the so-called "Randle shift": a process of transition to more oxygen-efficient ATP generation from glucose utilization [17] .
However, it appears possible to improve efficiency of myocardial oxygen utilization by more than the 13% -15% expected from activation of a "Randle shift" [18] . Many of the agents concerned exert multiple effects, including interactions with "energy sensor" such as AMP kinase (AMPK) and the pro-oxidant thioredoxin-interacting protein (TxNIP). Specifically, metformin, which reduces mortality in diabetics, is an AMPK activator, and ACE inhibitors, among their many effects, reduce TxNIP expression. Amiodarone, apart from its anti-anginal effects through β-blockade/calcium channel blockade, also blocks the "carnitine shuttle" [19] .
However, of the numerous agents with "metabolic" anti-ischaemic actions, there are of particular significance: perhexiline, trimetazidine and ranolazine. These will be discussed more fully.
Perhexiline
Perhexiline is a myocardial "metabolic" agent that was introduced in the 1970s as a prophylactic anti-anginal agent which was initially presumed to be a coronary vasodilator. Perhexiline proved to be an extremely effective treatment for exertional angina, whether in monotherapy [20] or in combination with other agents [21] . Despite its early success, its use was rapidly declined after reports of serious hepato-and neurotoxicity associated with long-term administration, which was poorly understood at that time. In the mid 1980s, many countries removed it from their markets following those reports. However, hepato-and neurotoxicity was later recognised to be attributable to drug accumulation, by virtue of inter-individual variability in pharmacokinetics, due to genetic polymorphism of cytochrome P450 2D6. Subsequently, significant long-term side effects were shown to be largely eliminated by dosage adjustment according to plasma perhexiline concentrations [22] [23] .
Although there were early proposals about the potential "myocardial metabolic" effects of perhexiline, it was not until in 1996 [19] (almost 30 years after it was used clinically as an anti-anginal) that it was found to be a potent inhibitor of the carnitine shuttle. Inhibition of carnitine palmitoyl transferase-1 (CPT-1), and to a lesser extent, CPT-2 [24] led to secondary activation of glucose utilization via increased pyruvate dehydogenase activity, as a component of the "Randle cycle".
This metabolic shift in theory resulted in greater glucose utilization, and therefore increased ATP production. These findings therefore provide a potential explanation of the anti-ischaemic benefit of the drug. However, it was later shown that in working non-ischaemic rat hearts, perhexiline increased cardiac efficiency by approximately 30%, without reduction of long-chain fatty acid utilization under these conditions [25] . As inhibition of CPT-1 and 2 could not have accounted for all these effects, it has been suggested that there are additional mechanisms of therapeutic action. Indeed, subsequent studies showed that perhexiline possess some "anti-inflamematory" effects, including potentiation of nitric oxide [26] . It also inhibits superoxide formation in intact neutrophils, aortic valve interstitial cells, human umbilical vein endothelial cells and NADPH oxidase-2 [27] [28] , and reduces expression of TXNIP in human cardiac tissue [29] .
Clinically, beyond its well-known anti-anginal effect, clinical efficacy of perhexiline has also been demonstrated in symptomatic inoperable aortic stenosis [30] , systolic heart failure [31] and in symptomatic non-obstructive hypertrophic cardiomyopathy [32] . In the latter study, despite the relatively short duration of treatment, perhexiline demonstrated improvement in myocardial energetic status (as measured by phosphocreatine to ATP ratios), oxygen consumption during peak exertion (peak VO 2 ), ejection fraction and symptomatic status.
Trimetazidine
Trimetazidine inhibits 3-ketoacyl thiolase, the terminal enzyme involved in β-oxidation. It has therefore been shown to inhibit fatty acid oxidation in vitro and in vivo. It exerts moderate effects on exercise duration in patients with stable angina pectoris both as monotherapy [33] and in combination with β-blockers [34] [35] . It is widely used in Europe and Asia as anti-anginal treatment, without compromising haemodynamics. Similar to perhexiline, it has also been investigated in some small and relatively short clinical studies of heart failure, with promising endpoints focusing on left ventricular functions. Some of the studies also showed reduction in plasma cytokines and brain natriuretic peptide, suggesting its potential anti-inflammatory effect. However, it is noteworthy that there has been increasing reports of development of Parkinsonism after long-term treatment with trimetazidine. Although the rate is relatively low and the effect is usually reversible, such events should be evaluated and distinguished as a consequence of the individual agent or potentially of a particular drug class.
Ranolazine
Ranolazine has been utilized as an anti-anginal agent only relatively recently, with evidence of moderate efficacy, rather similar to that of trimetazidine [36] , and standard anti-anginal drugs [37] . Its main advantage has been freedom from major adverse effects, including safety in patients with heart failure. Initial studies suggested that ranolazine might act primarily as a partial fatty acid oxidation inhibitor [38] . However, more recently it has been suggested that inhibition of the late sodium current might contribute significantly to its anti-ischaemic effects [39] . Unlike perhexiline, human data on effects of ranolazine on myocardial energetic status are currently lacking. On the other hand, ranolazine appears to be devoid of major adverse effects.
Conclusions
There is an increasing evidence that elective coronary revascularization, except in the circumstance of surgical intervention for extensive ischaemia, lacks major prognostic impact. Furthermore, an increasing proportion of patients with severe stable angina pectoris are unsuitable for any form of coronary revascularization.
On the other hand, long-acting nitrates, β-blockers, and calcium antagonists are only moderately effective in improving angina symptoms, and there is therefore a considerable need for new anti-anginal drugs.
The emerging data suggest that ivabradine, allopurinol, trimetazidine, and ranolazine all offer some incremental effect, and can be utilized as "add-on" therapy in most patients, including those with impaired left ventricular systolic dysfunction. Perhexiline, while extremely potent as an anti-anginal agent, has potentially serious long-term toxicity and should be utilized only with therapeutic drug monitoring. There is no evidence that any of these agents is effective in treatment of angina induced by coronary vasomotor disorders: they appear to act essentially on the determinants of ATP availability to myocardium. The development of the "new" anti-ischaemic options serves to remind us of the need for further progress in this area.
